What an incredible experience being at #ESMOBreast25!
We’re so grateful to have been part of such an inspiring congress last week in Munich, surrounded by brilliant minds pushing the boundaries of breast cancer research and care. From clinical trial updates to honest conversations about patient experience and survivorship, the atmosphere was rich with insight, collaboration, and a shared commitment to improving outcomes for people living with breast cancer.
Standout moments for the Lucid team:
*Realisation of the long-term overall survival benefits of dual HER2 blockade in the adjuvant setting, with presentation of the final OS data from the APHINITY trial
*Hearing how novel and established ADCs are reshaping the treatment landscapes across the spectrum of breast cancer subtypes
*Gaining insights into advances in immunotherapy for TNBC and the development of promising novel IO-drug combinations in early-stage clinical development
*Innovative, biomarker-led trial designs, generating data to guide de-escalation strategies and the use of chemotherapy-free drug regimens, and delivery of personalised medicine
*Learning more about the use of biomarkers for optimising the patient experience, such as the use of ctDNA, TILs, OncotypeDX and HER2DX, for estimating treatment responses, predicting relapses, and tracking resistance to therapy
*Engaging discussions around AI innovation in risk assessment and routine screening
Events like this remind us why we do what we do and we’re proud to play our part in translating science into impact.
Lucy Wade, Anthony Zucker, Hannah Greenwood
ESMO - European Society for Medical Oncology
#ESMOBreast
#BreastCancerResearch
#Oncology
#CancerResearch
#Immunotherapy
#ClinicalTrials
#InnovationInHealthcare
#TransformingLives